Enantioselective organocatalytic approaches to active pharmaceutical ingredients – selected industrial examples

References

[1] In: Blaser H-U, Schmidt E, editor(s). Asymmetric catalysis on industrial scale: challenges, approaches and solutions. Weinheim, Germany: Wiley-VCH, 2004Suche in Google Scholar

[2] In: Dalko P, editor(s). Comprehensive Enantioselective Organocatalysis (3 Volumes). Weinheim, Germany: Wiley-VCH, 201310.1002/9783527658862Suche in Google Scholar

[3] In: List B, editor(s). Asymmetric organocatalysis, in topics in current chemistry, 2010. Berlin, Germany and New York, USA: Springer-Verlag, 2009:19110.1007/978-3-642-02815-1Suche in Google Scholar

[4] In: Rios Torres R, editor(s). Stereoselective Organocatalysis. Hoboken, New Jersey, USA: Wiley, 201310.1002/9781118604755Suche in Google Scholar

[5] Melchiorre P, Marigo M, Carlone A, Bartoli B. Asymmetric aminocatalysis—gold rush in organic chemistry. Angew Chem Int Ed. 2008;47:6138–71.10.1002/anie.200705523Suche in Google Scholar PubMed

[6] Ahrendt KA, Borths CJ, MacMillan DWC. New strategies for organic catalysis: the first highly enantioselective organocatalytic Diels−Alder reaction. J Am Chem Soc. 2000;122:4243–4.10.1021/ja000092sSuche in Google Scholar

[7] List B, Lerner RA, Barbas III CF. Proline-catalyzed direct asymmetric aldol reactions. J Am Chem Soc. 2000;122:2395–6.10.1021/ja994280ySuche in Google Scholar

[8] MacMillan DWC. The advent and development of organocatalysis. Nature. 2008;455:304–8.10.1038/nature07367Suche in Google Scholar PubMed

[9] Marqués-López E, Herrera RP, Christmann M. Asymmetric organocatalysis in total synthesis – a trial by fire. Nat Prod Rep. 2010;27:1138–67.10.1039/b924964hSuche in Google Scholar PubMed

[10] Alemán J, Cabrera S. Applications of asymmetric organocatalysis in medicinal chemistry. Chem Soc Rev. 2013;42:774–93.10.1039/C2CS35380FSuche in Google Scholar PubMed

[11] Abbasov ME, Romo D. The ever-expanding role of asymmetric covalent organocatalysis in scalable, natural product synthesis. Nat Prod Rep. 2014;31:1318–27.10.1039/C4NP00025KSuche in Google Scholar PubMed PubMed Central

[12] Sun BF. Total synthesis of natural and pharmaceutical products powered by organocatalytic reactions. Tetrahedron Lett. 2015;56:2133–40.10.1016/j.tetlet.2015.03.046Suche in Google Scholar

[13] Merad J, Lalli C, Bernadat G, Maury J, Masson G. Enantioselective Brønsted acid catalysis as a tool for the synthesis of natural products and pharmaceuticals. Chem Eur J. 2018;24:3925–43.10.1002/chem.201703556Suche in Google Scholar PubMed

[14] Hughes DL. Asymmetric organocatalysis in drug development – highlights of recent patent literature. Org Process Res Dev. 2018;22:574–84.10.1021/acs.oprd.8b00096Suche in Google Scholar

[15] Hajos ZG, Parrish DR. Asymmetric synthesis of bicyclic intermediates of natural product chemistry. J Org Chem. 1974;39:1615–21.10.1021/jo00925a003Suche in Google Scholar

[16] Eder U, Sauer G, Wiechert R. New type of asymmetric cyclization to optically active steroid CD partial structures. Angew Chem Int Ed. 1971;10:496–7.10.1002/anie.197104961Suche in Google Scholar

[17] Dolling U-H, Davis P, Grabowski EJJ. Efficient catalytic asymmetric alkylations. 1. Enantioselective synthesis of (+)-indacrinone via chiral phase-transfer catalysis. J Am Chem Soc. 1984;106:446–7.10.1021/ja00314a045Suche in Google Scholar

[18] Maruoka K. Practical aspects of recent asymmetric phase-transfer catalysis. Org Process Res Dev. 2008;12:679–97.10.1021/op7002979Suche in Google Scholar

[19] Tan J, Yasuda N. Contemporary asymmetric phase transfer catalysis: large-scale industrial applications. Org Process Res Dev. 2015;19:1731–46.10.1021/acs.oprd.5b00304Suche in Google Scholar

[20] For a selection of examples, see the special feature section. Org Process Res Dev. 2011;15:1088–211.10.1021/op200214dSuche in Google Scholar

[21] Butters M, Catterick D, Craig A, Curzons A, Dale D, Gillmore A, et al. Critical assessment of pharmaceutical processess - a rationale for changing the synthetic route. Chem Rev. 2006;106:3002–27.10.1021/cr050982wSuche in Google Scholar PubMed

[22] In: Blaser H-U, Federsel H-J, editor(s). Asymmetric catalysis on industrial scale: challenges, approaches and solutions, Second ed. Weinheim, Germany: Wiley-VCH . see Chapters 9, 26, 27 201110.1002/9783527630639Suche in Google Scholar

[23] Xu F. Organocatalysis for asymmetric synthesis – from lab to factory. In: Dunn PJ, Hi KK (M), Krische MJ, Williams MT, editor(s). Sustainable catalysis - challenges and practices for the pharmaceutical and fine chemical industries. Hoboken, New Jersey, USA: Wiley. Chapter 14 2013:317–38.10.1002/9781118354520.ch14Suche in Google Scholar

[24] Scott JP, Ashwood MS, Brands KM, Brewer SE, Cowden CJ, Dolling UH, et al. Development of a phase transfer catalyzed asymmetric synthesis for an estrogen receptor beta selective agonist. Org Process Res Dev. 2008;12:723–30.10.1021/op700178qSuche in Google Scholar

[25] Xu F, Zacuto M, Yoshikawa N, Desmond R, Hoerrner S, Itoh T, et al. Asymmetric synthesis of telcagepant, a CGRP receptor antagonist for the treatment of migraine. J Org Chem. 2010;75:7829–41.10.1021/jo101704bSuche in Google Scholar PubMed

[26] Xu F, Corley E, Zacuto M, Conlon DA, Pipik B, Humphrey G, et al. Asymmetric synthesis of a potent, aminopiperidine-fused imidazopyridine dipeptidyl peptidase IV inhibitor. J Org Chem. 2010;75:1343–53.10.1021/jo902573qSuche in Google Scholar PubMed

[27] Yue T-Y, McLeod DD, Albertson KB, Beck S R, Deerberg J, Fortunak JM, et al. Stereoselective process for a CCR3 antagonist. Org Process Res Dev. 2006;10:262–71.10.1021/op050202lSuche in Google Scholar

[28] Jiang X, Gong B, Prasad K, Repič O. A practical synthesis of a chiral analogue of FTY720. Org Process Res Dev. 2008;12:1164–9.10.1021/op800144hSuche in Google Scholar

[29] Ishii Y, Fujimoto R, Mikami M, Murakami S, Miki Y, Furukawa Y. Practical syntheses of chiral α-amino acids and chiral half-esters by kinetic resolution of urethane-protected α-amino acid N-carboxyanhydrides and desymmetrization of cyclic meso-anhydrides with new modified Cinchona alkaloid catalysts. Org Process Res Dev. 2007;11:609–15.10.1021/op700023hSuche in Google Scholar

[30] Ager DJ, Anderson K, Oblinger E, Shi Y, VanderRoest J. An epoxidation approach to a chiral lactone: application of the Shi epoxidation. Org Process Res Dev. 2007;11:44–51.10.1021/op060140eSuche in Google Scholar

[31] Mittendorf J, Benet-Buchholz J, Fey P, Mohrs KH. Efficient asymmetric synthesis of β-amino acid BAY 10-8888/PLD-118, a novel antifungal for the treatment of yeast infections. Synthesis. 2003;1:136–4010.1055/s-2003-36265Suche in Google Scholar

[32] Verghese PS, Schleiss MR. Letermovir. Treatment of human cytomegalovirus infection, Antiinfective agent. Drugs Future. 2013;38:291–8.10.1358/dof.2013.038.05.1946425Suche in Google Scholar PubMed PubMed Central

[33] Goossen K, Kuhn O, Berwe M, Krüger J, Militzer H-C. Process for the preparation of dihydroquinazolines. US20090221822.Suche in Google Scholar

[34] Humphrey GR, Dalby S M, Andreani T, Xiang B, Luzung MR, Song ZJ, et al. Asymmetric synthesis of letermovir using a novel phase-transfer-catalyzed aza-Michael reaction. Org Process Res Dev. 2016;20:1097–103.10.1021/acs.oprd.6b00076Suche in Google Scholar

[35] Luzung M, Humphrey GR, Xiang B, Belyk K M, Dalby SM, Schwab W, et al. Process for the preparation of substituted quinazoline compounds. WO2015088931 A1.Suche in Google Scholar

[36] Xiang B, Belyk K M, Reamer RA, Yasuda N. Discovery and application of doubly quaternized cinchona-alkaloid-based phase-transfer catalysts. Angew Chem Int Ed. 2014;53:8375–8.10.1002/anie.201404084Suche in Google Scholar PubMed

[37] Chung CK, Liu Z, Lexa KW, Andreani T, Xu Y, Ji Y, et al. Asymmetric hydrogen bonding catalysis for the synthesis of dihydroquinazoline-containing antiviral, letermovir. J Am Chem Soc. 2017;139:10637–40.10.1021/jacs.7b05806Suche in Google Scholar PubMed

[38] Dutschman GE, Grill SP, Gullen EA, Haraguchi K, Takeda S, Tanaka H, et al. Novel 4-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob Agents Chemother. 2004;48:1640–6.10.1128/AAC.48.5.1640-1646.2004Suche in Google Scholar PubMed PubMed Central

[39] Cheng Y-C, Tanaka H, Baba M Antiviral nucleosides analogs and methods for treating viral infections, especially HIV. US7,589,078.Suche in Google Scholar

[40] Cotte L, Dellamonica P, Raffi F, Yazdanpanah Y, Michel Molina J-M M, Boué F, et al. Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV-NRTI, in treatment-experienced HIV-1–infected subjects. Immune Defic Syndr. 2013;63:346–54.10.1097/QAI.0b013e3182965d12Suche in Google Scholar PubMed

[41] Wang F, Flint OP. BMS-986001, an HIV nucleoside reverse transcriptase inhibitor, does not degrade mitochondrial DNA in long-term primary cultures of cells isolated from human kidney, muscle, and adipose tissue. Antimicrob Agents Chemother. 2013;57:6205.10.1128/AAC.01206-13Suche in Google Scholar PubMed PubMed Central

[42] Eastgate MD, Schmidt MA, Fandrick KR. On the design of complex drug candidate syntheses in the pharmaceutical industry. Nature Rev. 2017;1:1–16.10.1038/s41570-017-0016Suche in Google Scholar

[43] Nagai K, Kiguchi S, Koyama H, Hume WE, Tsujimoto S. Method for producing 4′ethynyl d4T. US20100280235.Suche in Google Scholar

[44] Gallagher WP, Deshpande PP, Li J, Katipally K, Sausker J. A Claisen approach to 4′Ed4T. Org Lett. 2015;17:14–7.10.1021/ol503095vSuche in Google Scholar PubMed

[45] Gallagher WP, Deshpande PP, Li J, Katipally K Method for producing festinavir using 5-methyluridine as starting material. WO2014/172264.Suche in Google Scholar

[46] Ortiz A, Benkovics T, Beutner GL, Shi Z, Bultman M, Nye J, et al. Scalable synthesis of the potent HIV inhibitor BMS-986001 by non-enzymatic dynamic kinetic asymmetric transformation (DYKAT). Angew Chem Int Ed. 2015;54:7185–8.10.1002/anie.201502290Suche in Google Scholar PubMed

[47] Ortiz A, Benkovics T, Shi Z, Deshpande PP, Guo Z, Kronenthal DR, et al. Sulfilimine and sulfoxide methods for the preparation of festinavir. WO2013177243A1.Suche in Google Scholar

[48] Ji Y, Benkovics T, Beutner GL, Sfouggatakis C, Eastgate MD, Blackmond DG. Mechanistic insights into the vanadium-catalyzed Achmatowicz rearrangement of furfurol. J Org Chem. 2015;80:1696–702.10.1021/jo502641dSuche in Google Scholar PubMed

[49] Benkovics T, Ortiz A, Guo Z, Goswami A, Deshpande P. Enantioselective preparation of (S)-5-oxo-5,6-dihydro-2 H-pyran-2-yl benzoate. Org Synth. 2014;91:293–306.10.15227/orgsyn.091.0293Suche in Google Scholar

[50] Wilson LJ, Liotta D. A general method for controlling glycosylation stereochemistry in the synthesis of 2′-deoxyribose nucleosides. Tetrahedron Lett. 1990;31:1815–8.10.1016/S0040-4039(00)98793-8Suche in Google Scholar

[51] Mayes BA, Stewart AJ, Moussa AM D-Amino acid compounds for liver disease. WO2013177219A1.Suche in Google Scholar

[52] Gosselin G, Parsy CC, Alexandre F-R, Rahali H, Griffon J-F, Milhau J, et al. 2′-Chloro nucleoside analogs for HCV infection. WO2014058801A1.Suche in Google Scholar

[53] Press release Sep 2017: http://investors.merck.com/news/press-release-details/2017/Merck-Discontinues-MK-3682B-and-MK-3682C-Development-Programs/default.aspx.Suche in Google Scholar

[54] Cahard D, McGuigan C, Balzarini J. Aryloxy phosphoramidate triesters as Pro-Tides. Mini Rev Med Chem. 2004;4:371–81.10.2174/1389557043403936Suche in Google Scholar PubMed

[55] Ross BS, Reddy PG, Zhang H-R, Rachakonda S, Sofia MJ. Synthesis of diastereomerically pure nucleotide phosphoramidates. J Org Chem. 2011;76:8311–19.10.1021/jo201492mSuche in Google Scholar PubMed

[56] Simmons BL, Campos KR, Klapars A, Stewart AJ, Mayes BA, Maligres PE, et al. Process for making nucleoside phosphoramidate compounds. WO2016064797A1.Suche in Google Scholar

[57] DiRocco DA, Ji Y, Sherer EC, Klapars A, Reibarkh M, Dropinski J, et al. A multifunctional catalyst that stereoselectively assembles prodrugs. Science. 2017;356:426–30.10.1126/science.aam7936Suche in Google Scholar PubMed

[58] Press release March 2018: http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2336851.Suche in Google Scholar

[59] Sclafani JA, Chen J, Levy DV, Reese H, Dimitri M, Mudipalli P, et al. The first asymmetric pilot-scale synthesis of TV-45070. Org Process Res Dev. 2017;21:1616–24.10.1021/acs.oprd.7b00237Suche in Google Scholar

[60] Cadieux J-J, Chafeev M, Chowdhury S, Fu J, Jia Q, Abel S, et al. Synthetic methods for spiro-oxindole compounds. U.S. Patent 8,445,696, May 21, 2013.Suche in Google Scholar

[61] Sun S, Fu J, Chowdhury S, Hemeon IW, Grimwood ME, Mansour TS Asymmetric syntheses of spiro-oxindole compounds useful as therapeutic agents. U.S. Patent 9,487,535, Nov 08, 2016.Suche in Google Scholar

[62] Lygo B, Wainwright PG. A new class of asymmetric phase-transfer catalysts derived from Cinchona alkaloids — application in the enantioselective synthesis of α-amino acids. Tetrahedron Lett. 1997;38:8595−8.10.1016/S0040-4039(97)10293-3Suche in Google Scholar

[63] Wang Y, Milkiewicz KL, Kaufman ML, He L, Landmesser NG, Levy DV, et al. Plant process for the preparation of cinchona alkaloid-based thiourea catalysts. Org Process Res Dev. 2017;21:408–13.10.1021/acs.oprd.7b00049Suche in Google Scholar

[64] Vakulya B, Varga S, Csámpai A, Soós T. Highly enantioselective conjugate addition of nitromethane to chalcones using bifunctional cinchona organocatalysts. Org Lett. 2005;7:1967−9.10.1021/ol050431sSuche in Google Scholar PubMed

[65] McCooey SH, Connon SJ, Accessible R. 9-epi-amino cinchona alkaloid derivatives promote efficient, highly enantioselective additions of aldehydes and ketones to nitroolefins. Org Lett. 2007;9:599–602.10.1021/ol0628006Suche in Google Scholar PubMed

[66] Cassani C, Martín-Rapún R, Arceo E, Bravo F, Melchiorre P. Synthesis of 9-amino(9-deoxy)epi Cinchona alkaloids, general chiral organocatalysts for the stereoselective functionalization of carbonyl compounds. Nat Protoc. 2013;8:325–44.10.1038/nprot.2012.155Suche in Google Scholar PubMed

[67] Sigman MS, Vachal P, Jacobsen EN. A general catalyst for the asymmetric Strecker reaction. Angew Chem Int Ed. 2000;39:1279–81.10.1002/(SICI)1521-3773(20000403)39:7<1279::AID-ANIE1279>3.0.CO;2-USuche in Google Scholar

[68] Zuend SJ, Jacobsen EN. Mechanism of amido-thiourea catalyzed enantioselective imine hydrocyanation: transition state stabilization via multiple non-covalent interactions. J Am Chem Soc. 2009;131:15358–74.10.1021/ja9058958Suche in Google Scholar PubMed

[69] Zuend SJ, Coughlin MP, Lalonde MP, Jacobsen EN. Scaleable catalytic asymmetric Strecker syntheses of unnatural α-amino acids. Nature. 2009;461:968–71.10.1038/nature08484Suche in Google Scholar PubMed

[70] Ooi T, Kameda M, Maruoka K. Molecular design of a C₂-symmetric chiral phase-transfer catalyst for practical asymmetric synthesis of α-amino acids. J Am Chem Soc. 1999;121:6519–20.10.1021/ja991062wSuche in Google Scholar

[71] Ikunaka M, Maruoka K. Asymmetric phase-transfer catalysis for the production of non-proteinogenic α-amino acids, chapter 9. In: Blaser H-U, Federsel H-J, editor(s). Asymmetric catalysis on industrial scale: challenges, approaches and solutions, 2nd ed. Weiheim, Germany.: Wiley-VCH, 2011:151–69.Suche in Google Scholar

[72] Bernardi L, Fochi M, Carbone R, Martinelli A, Fox ME, Cobley CJ, et al. Organocatalytic asymmetric conjugate additions to cyclopent-1-enecarbaldehyde: a critical assessment of organocatalytic approaches towards the telaprevir bicyclic core. Chem Eur J. 2015;21:19208–22.10.1002/chem.201503352Suche in Google Scholar

[73] Stevanović D, Bertuzzi G, Mazzanti A, Fochi M, Bernardi L. Catalytic enantioselective povarov reactions of ferrocenecarbaldehyde-derived imines – brønsted acid catalysis at parts-per-million level loading. Adv Synth Catal. 2018;360:893–900.10.1002/adsc.201701484Suche in Google Scholar